CD274 and cancer: As a biomarker of response to the immune checkpoint inhibitor, PD-L1 expression in tumor cells was shown to correlate with the efficacy of immunotherapy involving programmed death 1 (PD-1)/PD-L1 inhibitors in many cancers.